149 related articles for article (PubMed ID: 29688833)
1. Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study.
Hamood R; Hamood H; Merhasin I; Keinan-Boker L
J Clin Oncol; 2018 Jul; 36(20):2061-2069. PubMed ID: 29688833
[TBL] [Abstract][Full Text] [Related]
2. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
Hamood R; Hamood H; Merhasin I; Keinan-Boker L
Osteoporos Int; 2019 Jan; 30(1):187-200. PubMed ID: 30413856
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiovascular disease after radiotherapy in survivors of breast cancer: A case-cohort study.
Hamood R; Hamood H; Merhasin I; Keinan-Boker L
J Cardiol; 2019 Apr; 73(4):280-291. PubMed ID: 30587455
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
Chlebowski RT; Schottinger JE; Shi J; Chung J; Haque R
Cancer; 2015 Jul; 121(13):2147-55. PubMed ID: 25757699
[TBL] [Abstract][Full Text] [Related]
5. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer.
Rillamas-Sun E; Kwan ML; Iribarren C; Cheng R; Neugebauer R; Rana JS; Nguyen-Huynh M; Shi Z; Laurent CA; Lee VS; Roh JM; Huang Y; Shen H; Hershman DL; Kushi LH; Greenlee H
Breast Cancer Res Treat; 2023 Aug; 201(1):117-126. PubMed ID: 37326764
[TBL] [Abstract][Full Text] [Related]
6. Association of tamoxifen use and increased diabetes among Asian women diagnosed with breast cancer.
Sun LM; Chen HJ; Liang JA; Li TC; Kao CH
Br J Cancer; 2014 Oct; 111(9):1836-42. PubMed ID: 25225901
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors.
Haque R; Shi J; Schottinger JE; Ahmed SA; Cheetham TC; Chung J; Avila C; Kleinman K; Habel LA; Fletcher SW; Kwan ML
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26631176
[TBL] [Abstract][Full Text] [Related]
8. The prescription pattern of Chinese herbal products that contain dang-qui and risk of endometrial cancer among tamoxifen-treated female breast cancer survivors in Taiwan: a population-based study.
Wu CT; Lai JN; Tsai YT
PLoS One; 2014; 9(12):e113887. PubMed ID: 25485843
[TBL] [Abstract][Full Text] [Related]
9. Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women.
Santorelli ML; Hirshfield KM; Steinberg MB; Rhoads GG; Lin Y; Demissie K
Ann Epidemiol; 2016 Jun; 26(6):436-40. PubMed ID: 27157863
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
Xu X; Chlebowski RT; Shi J; Barac A; Haque R
Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431
[TBL] [Abstract][Full Text] [Related]
11. Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors.
Wadström H; Pettersson A; Smedby KE; Askling J
Ann Rheum Dis; 2020 May; 79(5):581-586. PubMed ID: 32161056
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.
He W; Fang F; Varnum C; Eriksson M; Hall P; Czene K
J Clin Oncol; 2015 Jul; 33(20):2262-9. PubMed ID: 26033800
[TBL] [Abstract][Full Text] [Related]
13. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; Deschênes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
[TBL] [Abstract][Full Text] [Related]
15. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Powles TJ; Ashley S; Tidy A; Smith IE; Dowsett M
J Natl Cancer Inst; 2007 Feb; 99(4):283-90. PubMed ID: 17312305
[TBL] [Abstract][Full Text] [Related]
16. Associations between diabetes medication use and risk of second breast cancer events and mortality.
Calip GS; Yu O; Hoskins KF; Boudreau DM
Cancer Causes Control; 2015 Aug; 26(8):1065-77. PubMed ID: 25956271
[TBL] [Abstract][Full Text] [Related]
17. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
18. Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up.
Rosell J; Nordenskjöld B; Bengtsson NO; Fornander T; Hatschek T; Lindman H; Malmström PO; Wallgren A; Stål O; Carstensen J
Breast Cancer Res Treat; 2013 Apr; 138(2):467-73. PubMed ID: 23456195
[TBL] [Abstract][Full Text] [Related]
19. Association between tamoxifen treatment and diabetes: a population-based study.
Lipscombe LL; Fischer HD; Yun L; Gruneir A; Austin P; Paszat L; Anderson GM; Rochon PA
Cancer; 2012 May; 118(10):2615-22. PubMed ID: 21935915
[TBL] [Abstract][Full Text] [Related]
20. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
Keating NL; O'Malley AJ; Smith MR
J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
